Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 5/20 | 0.53 |
| ▸ | P2RY6 | Q15077 | 5/20 | 0.46 |
| ▸ | P2RY14 | Q15391 | 3/20 | 0.46 |
| ▸ | PYGM | P11217 | 1/20 | 0.44 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.41 |
| ▸ | TK1 | P04183 | 1/20 | 0.40 |
| ▸ | TK2 | O00142 | 1/20 | 0.40 |
| ▸ | P2RY2 | P41231 | 1/20 | 0.39 |
| ▸ | NT5E | P21589 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21552268 | 1.00 | TYMP (0.53) | TYMPP2RY6P2RY14PYGMHSP90AA1 | |
| SCHEMBL7264129 | 0.92 | TYMP (0.62) | TYMPP2RY6P2RY14PYGMP2RY2 | |
| SCHEMBL8197884 | 0.92 | TYMP (0.62) | TYMPP2RY6P2RY14PYGMP2RY2 | |
| SCHEMBL16401441 | 0.91 | TYMP (0.54) | TYMPHSP90AA1TK1TK2 | |
| SCHEMBL16401440 | 0.91 | TYMP (0.54) | TYMPHSP90AA1TK1TK2 | |
| SCHEMBL21552210 | 0.90 | TYMP (0.53) | TYMPP2RY6P2RY14PYGMHSP90AA1 | |
| SCHEMBL21552211 | 0.90 | TYMP (0.53) | TYMPP2RY6P2RY14PYGMHSP90AA1 | |
| SCHEMBL26647522 | 0.87 | TYMP (0.51) | TYMPP2RY6HSP90AA1TK2NT5E | |
| SCHEMBL26647543 | 0.87 | TYMP (0.51) | TYMPP2RY6HSP90AA1TK2NT5E | |
| SCHEMBL22983983 | 0.85 | TYMP (0.53) | TYMPP2RY6P2RY14P2RY2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | SHIVALILA CHIKDU SHAKTI (US) | 2025-10-02 | — | — | US | disclosed |
| US-12397013-B2 | Extrahepatic delivery | ALNYLAM PHARMACEUTICALS, INC. (US) | 2025-08-26 | — | — | US | disclosed |
| US-20250262235-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD (SG) | 2025-08-21 | — | — | US | disclosed |
| EP-4522744-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | Wave Life Sciences Ltd. (SG) | 2025-03-19 | — | — | EP | disclosed |
| EP-4507700-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | Wave Life Sciences Ltd. (SG) | 2025-02-19 | — | — | EP | disclosed |
| US-20240358738-A1 | EXTRAHEPATIC DELIVERY | BANK OF AMERICA, N.A. | 2024-10-31 | — | — | US | disclosed |
| US-12005074-B2 | Extrahepatic delivery | ALNYLAM PHARMACEUTICALS, INC. (US) | 2024-06-11 | — | — | US | disclosed |
| US-20240009225-A1 | EXTRAHEPATIC DELIVERY | BANK OF AMERICA, N.A. | 2024-01-11 | — | — | US | disclosed |
| WO-2023220440-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023220428-A1 | COMPOSITIONS FOR EDITING ASS1 TRANSCRIPTS AND METHODS THEREOF | WAVE LIFE SCIENCES LTD. (SG) | 2023-11-16 | — | — | WO | disclosed |
| WO-2023201095-A2 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | WAVE LIFE SCIENCES LTD. (SG) | 2023-10-19 | — | — | WO | disclosed |
| US-20220307024-A1 | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM | ALNYLAM PHARMACEUTICALS, INC. (US) | 2022-09-29 | — | — | US | disclosed |
| US-20220125823-A1 | EXTRAHEPATIC DELIVERY | BANK OF AMERICA, N.A. | 2022-04-28 | — | — | US | disclosed |
| EP-3983077-A1 | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM | Alnylam Pharmaceuticals, Inc. (US) | 2022-04-20 | — | — | EP | disclosed |
| EP-3790970-A1 | EXTRAHEPATIC DELIVERY | Alnylam Pharmaceuticals Inc. (US) | 2021-03-17 | — | — | EP | disclosed |
| WO-2020257194-A1 | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM | ALNYLAM PHARMACEUTICALS, INC. (US) | 2020-12-24 | — | — | WO | disclosed |
| WO-2019217459-A1 | EXTRAHEPATIC DELIVERY | ALNYLAM PHARMACEUTICALS, INC. (US) | 2019-11-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220307024-A1 | DELIVERY OF OLIGONUCLEOTIDES TO THE STRIATUM | SNRPE, AGO2, IGF2BP2 | TYMP 1147/4885P2RY6 4557/4885P2RY14 4741/4885 |
| US-20250302995-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS THEREOF | ADAR, NSUN2, RNGTT | TYMP 82/4885P2RY6 404/4885P2RY14 895/4885 |
| US-20250262235-A1 | OLIGONUCLEOTIDE COMPOSITIONS AND METHODS RELATING THERETO | ADAR, RNGTT, NSUN2 | TYMP 36/4885P2RY6 2186/4885P2RY14 2992/4885 |
| US-20240358738-A1 | EXTRAHEPATIC DELIVERY | RNASE1, SLC10A1, FABP1 | TYMP 760/4885P2RY6 4304/4885P2RY14 4783/4885 |
| US-12005074-B2 | Extrahepatic delivery | RNASE1, SLC10A1, FABP1 | TYMP 760/4885P2RY6 4304/4885P2RY14 4783/4885 |
| US-20220125823-A1 | EXTRAHEPATIC DELIVERY | RNASE1, LDLR, HAVCR2 | TYMP 995/4885P2RY6 4318/4885P2RY14 4818/4885 |
| US-20240009225-A1 | EXTRAHEPATIC DELIVERY | RNASE1, SLC10A1, FABP1 | TYMP 760/4885P2RY6 4304/4885P2RY14 4783/4885 |
| US-12397013-B2 | Extrahepatic delivery | RNASE1, LDLR, HAVCR2 | TYMP 995/4885P2RY6 4318/4885P2RY14 4818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.